Table 3. Cardiovascular risk of seropositive arthralgia patients and age and sex matched seronegative controls.
| Seropositive arthralgia patients | Seronegative controls | p | |
|---|---|---|---|
| N = 71 * | N = 71 | ||
| TC1 (mean ±SD) | 5.4 (0.9) | 4.9 (0.8) | <0.001 |
| HDL1 (mean ±SD) | 1.4 (0.5) | 1.7 (0.4) | <0.001 |
| TC/HDL ratio1 (median, IQR) | 4.0 (3.4–5.0) | 3.0 (2.4–3.5) | <0.001 |
| LDL1 (mean ±SD) | 3.2 (0.9) | 2.9 (0.8) | 0.098 |
| Triglycerides1 (median ±IQR) | 1.4 (1.0–2.1) | 1.0 (0.7–1.5) | 0.001 |
| ApoA2 (mean ±SD) | 1.6 (0.3) | 1.6 (0.2) | 0.736 |
| ApoB2 (mean ±SD) | 1.0 (0.2) | 0.9 (0.2) | 0.019 |
| SCORE (median, IQR) | 1.00 (0.00–2.00) | 0.00 (0.00–1.00) | 0.01 |
| QRISK3 (median, IQR) | 4.4 (2.0–9.8) | 3.1 (1.5–6.2) | 0.03 |
| QRISK3 relative risk (median, IQR) | 1.5 (1.1–1.9) | 1.0 (0.8–1.2) | <0.001 |
* Of 71 patients, 15 (21%) developed arthritis
1 Subjects using cholesterol lowering medication were excluded from analyses. Included: n = 133 (seropositive patients: 67, seronegative controls: 66).
2 APOA and APOB were measured in a subset of seronegative controls (n = 37) and all seropositive patients (n = 67 excluding statin users).
ApoA: apolipoprotein A, ApoB: apolipoprotein B, HDL: high density lipoprotein, LDL: low density lipoprotein, TC: total cholesterol, TC/HDL ratio: total cholesterol / high density lipoprotein ratio.